205 related articles for article (PubMed ID: 33516737)
1. Exposure of R6/2 mice in an enriched environment augments P42 therapy efficacy on Huntington's disease progression.
Couly S; Carles A; Denus M; Benigno-Anton L; Maschat F; Maurice T
Neuropharmacology; 2021 Mar; 186():108467. PubMed ID: 33516737
[TBL] [Abstract][Full Text] [Related]
2. Improvement of BDNF signalling by P42 peptide in Huntington's disease.
Couly S; Paucard A; Bonneaud N; Maurice T; Benigno L; Jourdan C; Cohen-Solal C; Vignes M; Maschat F
Hum Mol Genet; 2018 Sep; 27(17):3012-3028. PubMed ID: 29860423
[TBL] [Abstract][Full Text] [Related]
3. Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.
Arribat Y; Talmat-Amar Y; Paucard A; Lesport P; Bonneaud N; Bauer C; Bec N; Parmentier ML; Benigno L; Larroque C; Maurel P; Maschat F
Acta Neuropathol Commun; 2014 Aug; 2():86. PubMed ID: 25091984
[TBL] [Abstract][Full Text] [Related]
4. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
5. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.
Simmons DA; Belichenko NP; Yang T; Condon C; Monbureau M; Shamloo M; Jing D; Massa SM; Longo FM
J Neurosci; 2013 Nov; 33(48):18712-27. PubMed ID: 24285878
[TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
7. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
[TBL] [Abstract][Full Text] [Related]
8. Responses to environmental enrichment differ with sex and genotype in a transgenic mouse model of Huntington's disease.
Wood NI; Carta V; Milde S; Skillings EA; McAllister CJ; Ang YL; Duguid A; Wijesuriya N; Afzal SM; Fernandes JX; Leong TW; Morton AJ
PLoS One; 2010 Feb; 5(2):e9077. PubMed ID: 20174443
[TBL] [Abstract][Full Text] [Related]
9. Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.
Dai Y; Dudek NL; Li Q; Fowler SC; Muma NA
J Neurosci; 2009 Sep; 29(37):11550-9. PubMed ID: 19759302
[TBL] [Abstract][Full Text] [Related]
10. 'Super-Enrichment' Reveals Dose-Dependent Therapeutic Effects of Environmental Stimulation in a Transgenic Mouse Model of Huntington's Disease.
Mazarakis NK; Mo C; Renoir T; van Dellen A; Deacon R; Blakemore C; Hannan AJ
J Huntingtons Dis; 2014; 3(3):299-309. PubMed ID: 25300333
[TBL] [Abstract][Full Text] [Related]
11. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
[TBL] [Abstract][Full Text] [Related]
12. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
13. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
[TBL] [Abstract][Full Text] [Related]
14. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
Mo C; Renoir T; Hannan AJ
Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
[TBL] [Abstract][Full Text] [Related]
15. Ellagic acid rescues motor and cognitive deficits in the R6/2 mouse model of Huntington's disease by lowering mutant huntingtin protein.
Sun X; Zhu J; Sun XY; Ji M; Yu XL; Liu RT
Food Funct; 2020 Feb; 11(2):1334-1348. PubMed ID: 32043503
[TBL] [Abstract][Full Text] [Related]
16. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
[TBL] [Abstract][Full Text] [Related]
17. Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.
Smail S; Bahga D; McDole B; Guthrie K
Chem Senses; 2016 Mar; 41(3):221-32. PubMed ID: 26783111
[TBL] [Abstract][Full Text] [Related]
18. Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies.
Brito V; Puigdellívol M; Giralt A; del Toro D; Alberch J; Ginés S
Cell Death Dis; 2013 Apr; 4(4):e595. PubMed ID: 23598407
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
[TBL] [Abstract][Full Text] [Related]
20. The P42 peptide and Peptide-based therapies for Huntington's disease.
Marelli C; Maschat F
Orphanet J Rare Dis; 2016 Mar; 11():24. PubMed ID: 26984770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
